NRX Pharmaceuticals Q1 2026 Earnings Wider Loss Despite No Revenue Stock Advances Century Communities Q1 2026 Earnings Strong EPS Beat Amid Mixed Market Signals ANNX Q1 2026 Earnings EPS Beat Surprise as ClinicalStage Biotech Tightens Cost Control Presurance Holdings Q1 2024 Earnings Surprise Profit Beats Estimates But Shares Slide on Revenue Disclosures TRIB Q4 2024 Earnings Significant EPS Miss with 27255 Surprise Revenue Not Disclosed Research Solutions Inc RSSS Tests Key Support Zone After Modest Decline Day One Biopharmaceuticals DAWN Holds Steady at 2153 Consolidating Between Key Levels Morgan Stanley Direct Lending Fund MSDL Holds Steady Near Resistance Level Air Products and Chemicals APD Holds Near 290 as Momentum Stalls Protara Therapeutics Q1 2026 Earnings NarrowerthanExpected Loss as Pipeline Advances